Generate Biomedicines inks $1B collaboration with Novartis

Generate:Biomedicines has announced a collaboration with Novartis to discover and develop protein therapeutics using its proprietary generative AI platform. This partnership aims to leverage Generate's advanced AI capabilities alongside Novartis' expertise in drug development, accelerating the creation of innovative therapeutics for various diseases. The collaboration is valued at over $1 billion, with an initial payment of $65 million.

Fiona Marshall from Novartis expressed excitement about using generative AI to enhance biologics discovery, while Generate's CEO, Mike Nally, emphasized the opportunity to tackle unmet medical needs:

“Partnering with a world-leading drug discovery and development organization like Novartis allows us to broaden the use of our cutting-edge generative biology platform to tackle even more areas of unmet medical need. We look forward to working closely with the team at Novartis to continue to demonstrate the transformative potential of programming biology to create better medicines for patients, faster.”

A key focus of this partnership is generative biology, which represents a shift towards creating novel therapeutic molecules through AI, offering a more effective approach to drug development compared to traditional methods. 

About Generate:Biomedicines 

Founded in 2018, Generate:Biomedicines aims to revolutionize medicine through programmable biology. Generate:Biomedicines is a new kind of therapeutics company—existing at the intersection of machine learning, biological engineering, and medicine—pioneering generative biology to create breakthrough medicines. Through The Generate Platform, the team is able to expand the breadth of technical possibilities in order to fundamentally change the way medicines are made.